Currently, an ongoing phase III, multicenter, randomized, sham-controlled, double-blind trial is evaluating AT-04s efficacy and safety for endometriosis-related pain (dysmenorrhea, dyspareunia, chronic pelvic pain), with the primary outcome being the change in Numeric Rating Scale score at 16 weeks ( 4.5 Disease heterogeneity and subtype-specific therapeutic strategies Endometriosis exhibits significant clinical and biological heterogeneity, encompassing diverse anatomical subtypessuperficial peritoneal endometriosis (SPE), ovarian endometriomas (OMA), and deep infiltrating endometriosis (DIE)each with distinct pathophysiological features, symptom profiles, and fertility implications ( Table 1 )
95% CI, 0.76-0.89) lowered the risk for worsening mental illness while exenatide and dulaglutide (Trulicity, Eli Lilly) did not
(2020) 2:E41827
This panel allows our clinicians to get a large and comprehensive picture of what is going on in your body which provides us with an opportunity to offer thorough and customized suggestions tailored to you based on your unique results to help you achieve optimal preventative health and wellness
Lancet 272 , 120123 (1957)